Research programme: implantable therapeutics - Valera PharmaceuticalsAlternative Names: Tamsulosin - Valera; VP 005; VP 006
Latest Information Update: 01 Feb 2007
At a glance
- Originator Valera Pharmaceuticals
- Mechanism of Action Alpha 1a adrenergic-receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Benign prostatic hyperplasia; Enuresis; Interstitial cystitis
Most Recent Events
- 01 Feb 2007 Discontinued - Preclinical for Enuresis in USA (SC)
- 01 Feb 2007 Discontinued - Preclinical for Interstitial cystitis in USA (SC)
- 01 Feb 2007 Discontinued - Preclinical for Benign prostatic hyperplasia in USA (SC)